Aequus Pharmaceuticals (AQS) AI Stock Analysis

• Market Cap: C$663.17K
• Dividend Yield: N/A
• Average Volume (3M): 65.80K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.48
• Revenue Growth: -29.63%
• EPS Growth: 17.89%
• Country: CA
• Employees: 12
• Sector: Healthcare
• Sector Strength: 65
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.02
• Shares Outstanding: 132,634,430
• 10 Day Avg. Volume: 54,393
• 30 Day Avg. Volume: 65,797
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 3.21
• Price to Cash Flow (P/CF): -1.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Aequus Pharmaceuticals is currently struggling with financial instability, as reflected in its low financial performance score. Technical analysis indicates a bearish trend, which, along with a negative P/E ratio, contributes to its low valuation score. The lack of earnings call data and corporate events leaves the primary focus on the company's financial challenges.

Aequus Pharmaceuticals Business Overview & Revenue Model

Company Description

Aequus Pharmaceuticals (AQS) is a specialty pharmaceutical company focused on enhancing patient care by developing and commercializing innovative and differentiated products in the field of ophthalmology, neurology, and transplant medicine. The company is committed to improving product delivery and increasing patient compliance through its proprietary delivery technologies and strategic partnerships. Aequus operates primarily in North America, leveraging its expertise in drug development and commercialization to bring both branded and generic products to market.

How the Company Makes Money

Aequus Pharmaceuticals generates revenue through the development, licensing, and commercialization of its pharmaceutical products. The company earns money by selling its proprietary and licensed products directly and through partnerships with other pharmaceutical companies. Revenue streams include product sales, licensing fees, and royalties from partnered products. Aequus also forms strategic alliances with larger pharmaceutical companies to co-promote or out-license its products, which can provide upfront payments, milestone payments, and ongoing royalties based on sales performance. These partnerships are crucial in expanding the company's market reach and maximizing the commercial potential of its product portfolio.

Aequus Pharmaceuticals Financial Statement Overview

Summary

Aequus Pharmaceuticals faces significant financial challenges, with declining revenues and increasing losses posing risks. The balance sheet is weakened by high leverage and negative equity, while cash flows are strained. Strategic financial restructuring is essential for stability.

Income Statement

The company has experienced declining revenue from previous years, with a significant drop in gross profit margin from strong levels in prior years to just 37.2% in TTM. The net profit margin remains negative due to consistent losses, reflecting operational challenges. Revenue growth is negative, indicating a need for strategic shifts.

Balance Sheet

The balance sheet is concerning with a negative stockholders' equity, resulting in an unsustainable debt-to-equity situation. Total debt has increased significantly, creating a high leverage risk. Equity ratio is not meaningful due to negative equity, indicating financial instability.

Cash Flow

The cash flow statement shows negative free cash flow with a declining trend, highlighting cash management issues. The ratio of operating cash flow to net income is negative, reflecting inefficiencies in converting earnings into cash. Financing activities are heavily relied upon for sustaining operations.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
413.17K	254.90K	1.38M	2.71M	2.59M	1.63M
	Gross Profit
153.83K	5.50K	1.15M	2.69M	2.59M	1.63M
	EBIT
-2.49M	-2.82M	-2.50M	-1.35M	-521.57K	-2.21M
	EBITDA
-2.31M	-2.68M	-2.87M	-1.23M	-314.80K	-2.38M
	Net Income Common Stockholders
-2.68M	-2.96M	-3.21M	-1.81M	-1.05M	-3.11M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
369.89K	170.20K	294.67K	2.39M	1.72M	484.51K
	Total Assets
2.00M	1.09M	1.69M	4.35M	3.13M	1.67M
	Total Debt
0.00	5.06M	782.92K	2.18M	2.32M	2.22M
	Net Debt
-369.89K	4.89M	533.10K	-211.31K	604.74K	1.73M
	Total Liabilities
314.90K	5.38M	3.07M	2.56M	2.56M	2.55M
	Stockholders Equity
1.68M	-4.29M	-1.38M	1.79M	573.95K	-877.09K
Cash Flow		Free Cash Flow
-2.48M	-2.29M	-1.95M	-1.18M	-817.23K	-1.63M
	Operating Cash Flow
-2.48M	-2.29M	-1.95M	-1.17M	-804.91K	-1.63M
	Investing Cash Flow
0.00	0.00	0.00	-507.96K	-12.32K	-2.68K
	Financing Cash Flow
2.39M	2.21M	-189.19K	2.40M	2.05M	1.75M

Aequus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AQS, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of <0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.51 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AQS.

Aequus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TRP	71 Outperform	$70.44B	15.31	16.85%	5.29%	5.31%	61.02%
NEO	67 Neutral	C$455.89M	―	-3.15%	3.92%	-15.41%	-69.47%
GUD	65 Neutral	$579.78M	132.50	0.53%	―	13.13%	―
BHC	55 Neutral	$2.80B	―	3.60%	―	11.61%	92.72%
HLS	54 Neutral	C$132.58M	―	-23.20%	―	-8.80%	26.77%
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%
AQS	38 Underperform	C$663.17K	―	43.02%	―	-29.63%	17.89%

Aequus Pharmaceuticals Corporate Events

Aequus Pharmaceuticals Reports Revenue Growth Amid Restructuring

Aequus Pharmaceuticals reports a 77.50% increase in revenue for Q3 2024 compared to the previous year, driven by the continued growth of their product Zimed® PF. The company has restructured to reduce costs amidst delayed profitability, while also exploring strategic alternatives to enhance future performance.